Traditional MedicareCoverageMedium impact
Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
Medicare/CMS - LCD·Hematology, Oncology, Pathology·Local Coverage Determination
Effective date
Apr 1, 2026
We identified it
Jul 28, 2026
Summary
This new Local Coverage Determination (LCD L37606) from Wellpoint Federal establishes coverage and billing guidelines for genomic sequence analysis panels used in the diagnosis and treatment of hematolymphoid diseases (blood and lymph cancers). The policy, effective April 1, 2026, defines which genomic tests are covered, medical necessity requirements, and billing standards for Medicare beneficiaries in Wellpoint's service area.
Action Required
By March 15, 2026: Billing team must obtain and review the complete LCD L37606 policy text from the CMS Medicare Coverage Database (URL provided). Identify all genomic sequence analysis panel CPT and HCPCS codes covered under this LCD. By March 31, 2026: Update billing software and EMR systems to reflect Wellpoint Federal's coverage requirements, including any prior authorization mandates, medical necessity documentation requirements, and applicable ICD-10 diagnosis codes for hematolymphoid diseases. Notify all providers ordering genomic panels of new documentation requirements and coverage limitations. Coordinate with lab partners to ensure compliance with billing codes and prior auth processes. Failure to comply may result in claim denials or recoupment of improperly billed services.